Abiraterone acetate plus prednisone and ADT is associated with improved health-related quality of life compared with ADT plus placebo among patients with metastatic castration-naïve prostate cancer.

News

At the Philadelphia Prostate Consensus Conference, a panel of experts addressed genetic counseling and testing, screening, and management in patients with prostate cancer.
A new clinical-genomic risk group classification may accurately identify patients at low, intermediate, and high risk for metastasis in localized prostate cancer.
Biopsies every 2 years, instead of annually, seem to be "an acceptable alternative" for acute surveillance of low-risk prostate cancer, according to a comparative analysis.
Positron emission tomography (PET)-based molecular imaging biomarkers may predict therapeutic response and survival in patients with metastatic castration-resistant prostate cancer (mCRPC).

Research in Review

Luminal and basal subtyping of prostate cancer may provide a clinical tool for predicting which patients will benefit from androgen deprivation therapy (ADT) after prostatectomy, according to a report published in JAMA Oncology (published online May 11, 2017; doi:10.1001/jamaoncol.2017.0751).

-----

Related Content

Read More

A 4-week precision radiotherapy regimen is as effective and safe as the standard 8-week regimen for treating localized prostate cancer, according to research published in the Journal of Clinical Oncology (published online March 15, 2017; doi:10.1200/JCO.2016.71.7397).

Read More

High-dose-rate brachytherapy administered in a single treatment may be a safe and effective alternative for patients with non-metastatic prostate cancer, according to a new study.

-----

Related Content

Read More

Taking one-fourth the recommended dose of a standard drug with a low-fat meal is as effective as taking the recommended dose on an empty stomach for patients with castration-resistant prostate cancer, according to research published in the Journal of Clinical Oncology (2017;35[suppl 6S]:abstract 176).

Read More

Subscribe to Prostate Cancer